RxDoctor Payments Data

Joshua Marcus, MD

Neurological Surgery · Danbury, CTNPI 1609010719

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $98,332 of the $141,922 with a category attached, or 69.3%. 29 manufacturers reported payments, led by Si-bone, Inc. at 45.9% of the total. Among neurological surgery clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$141,922in general payments, 2019–2025

Across 435 payments — averaging $326.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Si-bone, Inc.$65K
  • Globus Medical$34K
  • Premia Spine, Ltd.$18K
  • Depuy Synthes Products, Inc.$11K
  • Johnson & Johnson$3K
  • Boston Scientific$3K
  • plus $9K from 23 others
$100,000in ownership & investment interests, 2019–2025

Across 3 payments — averaging $33,333 each. An ownership or investment interest held by the physician or an immediate family member.

  • Vesalio, Inc.$100K

What the payments were for

  • Consulting fees$98,33269%
  • Speaking & faculty fees$15,60011%
  • Travel & lodging$11,5578%
  • Food & beverage$16,41412%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,922 in reported general payments places this provider in the 90th percentile of 94 neurological surgery providers in Connecticut.

See all neurological surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$381,269
Medicare patients
304
Services billed
1,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor16$9,674
Gabapentin37$326
Methocarbamol20$142
Meloxicam34$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$13$9,67416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 94 neurological surgery providers in Connecticut.

Other neurological surgery in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →